Stoke Therapeutics, Inc. STOK Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Stoke Therapeutics, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Stoke Therapeutics, Inc.'s investing cash flow?
- Stoke Therapeutics, Inc. (STOK) reported investing cash flow of $50.69M in Q1 2026.
- How has Stoke Therapeutics, Inc.'s investing cash flow changed year-over-year?
- Stoke Therapeutics, Inc.'s investing cash flow increased by 271.9% year-over-year, from $13.63M to $50.69M.
- What is the long-term trend for Stoke Therapeutics, Inc.'s investing cash flow?
- Over 2 years (2023 to 2025), Stoke Therapeutics, Inc.'s investing cash flow has grown at a 36.0% compound annual growth rate (CAGR), from $105.95M to -$195.91M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.